Human mismatch repair, drug-induced DNA damage, and secondary cancer

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• DNA mismatch repair (MMR) is a crucial mechanism for preventing mutations during DNA replication.
• Defects in MMR are associated with hereditary and sporadic gastrointestinal and endometrial cancers.
• MMR deficiency is increasingly observed in therapy-related acute myeloid leukaemia/myelodysplastic syndrome (AML/MDS) following chemotherapy.

Purpose of the Study:

• To review the interaction between MMR and DNA damage induced by alkylating agents and thiopurine drugs.
• To explore potential mechanisms for MMR defects in therapy-related AML/MDS.

Main Methods:

• Literature review of studies on DNA mismatch repair, chemotherapy, and hematological malignancies.
• Analysis of the mechanisms by which alkylating agents and thiopurines induce DNA damage.
• Examination of the role of MMR in the context of therapy-related AML/MDS.

Main Results:

• Therapy-related hematological malignancies, particularly AML/MDS, are often linked to alkylating agent treatment.
• MMR defects are associated with AML/MDS in patients treated with immunosuppressive thiopurine drugs.
• The frequency of therapy-related AML is increasing, accounting for at least 10% of all AML cases.

Conclusions:

• MMR plays a significant role in processing DNA damage caused by specific chemotherapeutic agents.
• Understanding MMR's interaction with DNA damage is key to elucidating the development of therapy-related AML/MDS.
• Further research into MMR defects may offer insights into preventing or treating these malignancies.